Kyowa Kirin and Kura Initiate Phase II Trial of Ziftomenib for AML

Why It Matters

The trial could secure Japan’s first approved menin‑inhibitor therapy, expanding treatment options for a high‑risk AML subset and strengthening Kyowa Kirin’s position in haematologic oncology.

Key Takeaways

• Phase II trial launched in Japan for ziftomenib in r/r NPM1‑AML.
• Primary endpoint is composite complete remission rate (CR + CRh).
• FDA approved ziftomenib (Komzifti) in Nov 2025 for relapsed AML.
• Kyowa Kirin seeks Japanese approval after trial data are submitted.
• Drug also being evaluated with standard and targeted therapies for front‑line AML.

Pulse Analysis

Acute myeloid leukaemia (AML) driven by NPM1 mutations remains a therapeutic challenge, especially after relapse or refractory disease. Menin inhibitors like ziftomenib target a key epigenetic driver, offering a mechanistic approach distinct from conventional chemotherapy. The Japanese Phase II study marks the first registrational effort for this class in Japan, reflecting growing confidence in precision‑medicine strategies for haematologic malignancies. By focusing on a composite remission endpoint that includes partial haematologic recovery, the trial aims to capture clinically meaningful benefits for patients who have exhausted standard options.

Ziftomenib’s recent U.S. FDA approval under the brand Komzifti validates its efficacy in a similar patient population, providing a regulatory precedent that Kyowa Kirin can leverage in Japan. The single‑arm, open‑label design expedites data collection while still delivering robust safety and efficacy signals required for Japanese Ministry of Health, Labour and Welfare approval. Success would not only grant Japanese patients access to a novel therapy but also position Kyowa Kirin as a leader in menin‑inhibitor development, potentially opening doors for future collaborations and market expansion across Asia.

Beyond monotherapy, Kyowa Kirin is testing ziftomenib alongside standard‑of‑care and targeted agents for front‑line AML with KMT2A translocations and FLT3 mutations. This combination strategy could broaden the drug’s applicability and address resistance mechanisms that limit current treatments. The parallel discontinuation of rocatinlimab underscores the company’s strategic focus on high‑impact haematologic products. If the Phase II results confirm the anticipated remission rates, ziftomenib could become a cornerstone of next‑generation AML regimens, influencing clinical practice and shaping the competitive landscape for biotech firms targeting epigenetic vulnerabilities.